For research use only. Not for therapeutic Use.
ML347 (LDN193719) is a highly selective ALK1/ALK2 inhibitor. ML347 has IC50 values of 46 and 32 nM against ALK1 and ALK2, respectively, >300-fold selective over ALK3. ML347 block the phosphorylation of Smad1/5 by TGF-β1[1][2].
ML347 can inhibit ALK1/ALK2 to block TGF?β signal transduction[2].
| Catalog Number | I000316 |
| CAS Number | 1062368-49-3 |
| Synonyms | 5-[6-(4-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline |
| Molecular Formula | C22H16N4O |
| Purity | ≥95% |
| InChI | InChI=1S/C22H16N4O/c1-27-17-9-7-15(8-10-17)16-12-24-22-20(13-25-26(22)14-16)18-4-2-6-21-19(18)5-3-11-23-21/h2-14H,1H3 |
| InChIKey | FVRYPYDPKSZGNS-UHFFFAOYSA-N |
| SMILES | COC1=CC=C(C=C1)C2=CN3C(=C(C=N3)C4=C5C=CC=NC5=CC=C4)N=C2 |
| Reference | [1]. Engers DW, et al. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. [2]. Zhang H, et al. Dual roles of TGF-β signaling in the regulation of dental epithelial cell proliferation. J Mol Histol. 2021 Feb;52(1):77-86. |
